Home / Companies / Sage Therapeutics, Inc. / 31 Jan 2024
Sage Therapeutics, Inc.: meeting of 31 Jan 2024
Votes reported on Form N-PX, item by item
118 Form N-PX filers reported votes at the Sage Therapeutics, Inc. meeting of 31 Jan 2024. Their records fall into 2 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
COMPENSATIONIssuer
COMPENSATION: management items
Management items in this category are shown together; filers word and number them differently.
226 vote records from 116 filers. 2 of the 114 filers that marked the item either way voted against management. 2 filers reported this item without a management mark.
CORPORATE GOVERNANCEIssuer
CORPORATE GOVERNANCE: management items
Management items in this category are shown together; filers word and number them differently.
227 vote records from 116 filers. 14 of the 114 filers that marked the item either way voted against management. 2 filers reported this item without a management mark.
How the largest families voted
None of the families tracked on this site reported a position on these items.
Questions
How did large funds vote at the Sage Therapeutics, Inc. meeting?
118 Form N-PX filers reported votes at the meeting of 31 Jan 2024. The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Sage Therapeutics, Inc. on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for Sage Therapeutics, Inc.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Sage Therapeutics, Inc. with a meeting date within three days of 31 Jan 2024. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 30 Sep 2026.